MCID: BLD044
MIFTS: 51

Bladder Disease malady

Categories: Nephrological diseases

Aliases & Classifications for Bladder Disease

Summaries for Bladder Disease

MedlinePlus : 41 the bladder is a hollow organ in your lower abdomen that stores urine. many conditions can affect your bladder. some common ones are cystitis - inflammation of the bladder, often from an infection urinary incontinence - loss of bladder control overactive bladder - a condition in which the bladder squeezes urine out at the wrong time interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination bladder cancer doctors diagnose bladder diseases using different tests. these include urine tests, x-rays, and an examination of the bladder wall with a scope called a cystoscope. treatment depends on the cause of the problem. it may include medicines and, in severe cases, surgery. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Bladder Disease, also known as urinary bladder diseases, is related to gallbladder disease and diphyllobothriasis, and has symptoms including bladder fullness sensation An important gene associated with Bladder Disease is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Calcium signaling pathway and Overview of nanoparticle effects. The drugs Hyaluronic acid and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and heart, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A urinary system disease that is located in the bladder.

Wikipedia : 71 Urinary bladder disease includes urinary bladder inflammation such as cystitis, bladder rupture and... more...

Related Diseases for Bladder Disease

Diseases related to Bladder Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Related Disease Score Top Affiliating Genes
1 gallbladder disease 10.7
2 diphyllobothriasis 10.5
3 malignant renovascular hypertension 10.2 NGF TAC1
4 inhalation anthrax 10.2 CRP TAC1 TRPV1
5 neuroendocrine tumor 10.2 NGF PPIG UPK3A
6 testicular leydig cell tumor 10.2 NGF TAC1 TRPV1
7 pseudoinflammatory fundus dystrophy 10.2 NGF TAC1
8 coloboma of iris 10.2 CRP IL6
9 simultanagnosia 10.2 IER3IP1 TAC1 TRPV1
10 uterine ligament serous adenocarcinoma 10.2 NGF TAC1 TRPV1
11 neuropathy 10.2 CRP HBEGF IL6
12 cervical carcinosarcoma 10.2 IER3IP1 TAC1 TRPV1
13 retinitis pigmentosa 51 10.1 CHRM3 CRP IL6
14 lymphocytic choriomeningitis 10.1 CHRM3 P2RX2
15 shoulder impingement syndrome 10.1 CRP IL6
16 generalized epilepsy with febrile seizures plus 10.1 NGF P2RX2 TAC1 TRPV1
17 tinea capitis 10.1 IL6 NGF TAC1 TRPV1
18 fuchs' heterochromic uveitis 10.1 KLK3 MCU UPK3A
19 uterine ligament clear cell adenocarcinoma 10.1 CRP IL6 TAC1 TRPV1
20 prostate small cell carcinoma 10.1 KLK3 NME1-NME2 UPK3A
21 peroneal neuropathy 10.1 CRP IER3IP1 IL6 TRPV1
22 keratomalacia 10.1 CRP IDO1 IL6
23 body dysmorphic disorder 10.1 CRP IER3IP1 IL6 TRPV1
24 acute chest syndrome 10.1 CRP IER3IP1 IL6 TAC1
25 calcinosis 10.1 CRP IL6 KLK3 TRPV1
26 substance-induced psychosis 10.0 IER3IP1 IL6 NGF TAC1
27 cutaneous sclerosis 10.0 CRP IL6
28 neurogenic bladder 9.9
29 pulmonary valve insufficiency 9.9 C16orf58 MCU UPK3A
30 uterine corpus dissecting leiomyoma 9.7 HBEGF IL6 NGF P2RX3 TAC1 TRPV1
31 bladder diverticulum 9.7
32 bladder calculus 9.7
33 prostatitis 9.6
34 neovascular glaucoma 9.4 CRP HBEGF IL6 NGF P2RX3 TAC1
35 allergic bronchopulmonary aspergillosis 9.4 C16orf58 CRP IER3IP1 IL6 KLK3 MCU
36 prostate calculus 9.4
37 interstitial cystitis 9.4
38 bacteriuria 9.4
39 myocardial infarction 9.4
40 cystitis 9.4
41 obesity 9.4
42 duodenal ulcer 9.4
43 pancreatic cancer 9.4
44 transitional cell carcinoma 9.4
45 hepatitis 9.4
46 pancreatitis 9.4
47 sinusitis 9.4
48 pneumonia 9.4
49 appendicitis 9.4
50 duodenitis 9.4

Comorbidity relations with Bladder Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Bladder Disease:



Diseases related to Bladder Disease

Symptoms & Phenotypes for Bladder Disease

UMLS symptoms related to Bladder Disease:


bladder fullness sensation

MGI Mouse Phenotypes related to Bladder Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.7 CHRM3 CRP HBEGF IDO1 IL6 MCU
2 homeostasis/metabolism MP:0005376 9.4 MCU NGF P2RX2 P2RX3 TERT TRPV1

Drugs & Therapeutics for Bladder Disease

Drugs for Bladder Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 761)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
2
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-84-3 187
3
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 5633-20-5 4634
4
Mirabegron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 223673-61-8
5
Fesoterodine Approved Phase 4,Phase 3,Phase 2,Phase 1 286930-02-7, 286930-03-8 6918558
6
Doxazosin Approved Phase 4 74191-85-8 3157
7
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 137-58-6 3676
8
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
9
Ethanol Approved Phase 4,Phase 3 64-17-5 702
10
Ciprofloxacin Approved, Investigational Phase 4,Phase 3 85721-33-1 2764
11
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2 723-46-6 5329
12
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 738-70-5 5578
13
Tamsulosin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 106133-20-4 129211
14
Trospium Approved Phase 4,Phase 3,Phase 1 10405-02-4, 47608-32-2 5596 5284631
15
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 2180-92-9, 38396-39-3 2474
16
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
17
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
18
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
19
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
20
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1 2216-51-5 16666
21
Prazosin Approved Phase 4,Phase 1,Phase 2 19216-56-9 4893
22
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
23
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3,Phase 2 67-20-9 5353830
24
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
25
Darifenacin Approved, Investigational Phase 4,Phase 3,Phase 2 133099-04-4 444031
26
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
27
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
28
Cefixime Approved Phase 4,Phase 3 79350-37-1 54362 5362065
29
Fosfomycin Approved Phase 4 23155-02-4 446987
30
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 53477736 447043
31
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
32
Silodosin Approved Phase 4,Phase 2 160970-54-7
33
Alfuzosin Approved, Investigational Phase 4,Phase 3,Phase 2 81403-80-7 2092
34
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
35
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2 76-42-6 5284603
36
Nicotine Approved Phase 4 54-11-5 942 89594
37
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
38
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
39
Memantine Approved, Investigational Phase 4 19982-08-2 4054
40
Cycloserine Approved Phase 4 68-41-7 401 6234
41
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
42
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
43
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 71273 175805
44
Cephalexin Approved, Vet_approved Phase 4,Phase 3,Phase 1 15686-71-2 27447
45
Desflurane Approved Phase 4 57041-67-5 42113
46
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
47
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
48 Parecoxib Approved Phase 4 198470-84-7
49
Ezogabine Approved Phase 4,Phase 3 150812-12-7 121892
50
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 2399)
id Name Status NCT ID Phase
1 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4
2 Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract Unknown status NCT02366676 Phase 4
3 Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity Unknown status NCT02009540 Phase 4
4 Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome Unknown status NCT00313924 Phase 4
5 Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Unknown status NCT01423838 Phase 4
6 MIrabegron With oveRACtive bLadder Symptoms in mEn Unknown status NCT02361502 Phase 4
7 Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. Unknown status NCT02468375 Phase 4
8 Efficacy Study of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy for Bladder Pain Syndrome Unknown status NCT01895153 Phase 4
9 Cost-Effectiveness in Bladder Cancer Unknown status NCT00126958 Phase 4
10 An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia Unknown status NCT00605319 Phase 4
11 Comparative Study of Mesh Versus No Mesh in Prolapse Surgery Unknown status NCT00153257 Phase 4
12 Surgical Treatment To Greater Anterior Vaginal Prolapse Unknown status NCT00676325 Phase 4
13 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4
14 Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome Unknown status NCT01157507 Phase 4
15 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4
16 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
17 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4
18 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4
19 Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients Unknown status NCT01570556 Phase 4
20 Gentamicin Bladder Instillation Trial Unknown status NCT01884467 Phase 4
21 Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients Unknown status NCT01772875 Phase 4
22 Efficacy and Safety of Floseal for the Haemostasis During Laparoscopic Cholecystectomy in Acute Cholecystitis (GLA) Unknown status NCT01126281 Phase 4
23 Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction Unknown status NCT01582542 Phase 4
24 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
25 Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery Surgery Unknown status NCT01889498 Phase 4
26 Comparison of Body and Room Temperature Saline in Urodynamics Unknown status NCT00355433 Phase 4
27 Treatment of Female Stress Urinary Incontinence: Study Comparing Two Suburethral Slings, Retropubic Approach (TVT) and Trans-Obturator (TVT-O) Approach Unknown status NCT00135616 Phase 4
28 Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients Unknown status NCT02006303 Phase 4
29 Efficiency of Cold vs. Laser Internal Urethrotomy Treatment of Urethral Strictures Unknown status NCT01196572 Phase 4
30 Pharmacological vs Surgical Treatment for Mixed Incontinence Unknown status NCT00523068 Phase 4
31 The Effect of Intravenous Lidocaine and Intraperitoneal Lidocaine Irrigation on Pain After Laparoscopic Cholecystectomy Unknown status NCT01608373 Phase 4
32 Interest of Intravaginal Electro-stimulation at Home by GYNEFFIK® Compared to Usual Care in Incontinent Patients With Prior Perineal Reeducation Unknown status NCT02029027 Phase 4
33 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
34 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4
35 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease Completed NCT01421719 Phase 4
36 Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease Completed NCT01018264 Phase 4
37 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4
38 A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department Completed NCT01749605 Phase 4
39 Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain Completed NCT02000401 Phase 4
40 Detrol LA In Men With Overactive Bladder. Completed NCT00282932 Phase 4
41 Therapy of the Overactive Bladder Syndrome Completed NCT01314781 Phase 4
42 Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome Completed NCT01824420 Phase 4
43 Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder Completed NCT00366002 Phase 4
44 Uro-NIRS Clinical Study Completed NCT00706407 Phase 4
45 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 Completed NCT01661621 Phase 4
46 Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients Completed NCT00902421 Phase 4
47 Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency Completed NCT00979472 Phase 4
48 Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. Completed NCT01093534 Phase 4
49 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Completed NCT01302054 Phase 4
50 Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4

Search NIH Clinical Center for Bladder Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Disease:
Neo-Urinary Conduit
Embryonic/Adult Cultured Cells Related to Bladder Disease:
Neo-Urinary Conduit PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder diseases

Genetic Tests for Bladder Disease

Anatomical Context for Bladder Disease

MalaCards organs/tissues related to Bladder Disease:

39
Testes, Kidney, Heart, Prostate, Smooth Muscle, Liver, Appendix

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Disease:

18
The Bladder

Publications for Bladder Disease

Articles related to Bladder Disease:

(show top 50) (show all 163)
id Title Authors Year
1
From gene discovery to new biological mechanisms: heparanases and congenital urinary bladder disease. ( 26315301 )
2015
2
Re: The Pharmacological rationale for combining muscarinic receptor antagonists and I^-adrenoceptor agonists in the treatment of airway and bladder disease. ( 25523672 )
2015
3
Prognostic Relevance of Human Telomerase Reverse Transcriptase (hTERT) Expression in Patients with Gall Bladder Disease and Carcinoma. ( 25854384 )
2015
4
Financial cost to institutions on patients waiting for gall bladder disease surgery. ( 25603667 )
2014
5
The pharmacological rationale for combining muscarinic receptor antagonists and I^-adrenoceptor agonists in the treatment of airway and bladder disease. ( 24682092 )
2014
6
Gastric pouch after simple or radical cystectomy for benign and malignant bladder disease. ( 25738108 )
2014
7
Genetics of human congenital urinary bladder disease. ( 23584850 )
2013
8
Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. ( 23013190 )
2012
9
Remodeling of the muscle layer (detrusor muscle) of hyperactive bladder disease in patients with benign prostatic hyperplasia. ( 23113284 )
2012
10
A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides. ( 21855919 )
2011
11
The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. ( 22046200 )
2011
12
Muscarinic acetylcholine receptor M3 mutation causes urinary bladder disease and a prune-belly-like syndrome. ( 22077972 )
2011
13
Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. ( 19634167 )
2010
14
A four-year-old with Streptococcus pneumoniae--associated hemolytic uremic syndrome and gall bladder disease necessitating cholecystectomy. ( 19286616 )
2009
15
Prevalence and characteristics associated with self-reported gall bladder disease in Mexican American elders: results from the Hispanic Established Populations for Epidemiologic Studies in the Elderly (H-EPESE). ( 19225267 )
2009
16
Overactive bladder disease: the urge for better therapies. ( 18500915 )
2008
17
TRPs in bladder diseases. ( 17560087 )
2007
18
Higher risk of gall bladder disease in oestrogen users. ( 28055473 )
2005
19
A study of the bacteriological pattern in gall bladder disease. 1986. ( 15485196 )
2004
20
Extracorporeal electromagnetic stimulation for urinary incontinence and bladder disease. ( 15088922 )
2003
21
In vivo optical coherence tomography feasibility for bladder disease. ( 11832776 )
2002
22
Electromagnetic pelvic floor stimulation for urinary incontinence and bladder disease. ( 11795645 )
2001
23
Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. ( 11167643 )
2001
24
Bladder disease: A report based on the smooth muscle function in health and disease satellite meeting to the International Congress of Physiology. ( 12734603 )
2001
25
Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. ( 11564042 )
2001
26
Review article: epidemiology of gall-bladder disease--role of intestinal transit. ( 10902996 )
2000
27
EAU - 15th Congress. Urinary incontinence and bladder disease. ( 16080050 )
2000
28
Nitric oxide synthase expression in neurogenic bladder disease: a pilot study. ( 10218094 )
1999
29
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen. ( 9471136 )
1998
30
Gall bladder disease and ABO blood group. ( 10456157 )
1997
31
Long-term follow-up after clam ileocystoplasty. Complications and results including some quality-of-life parameters for 32 patients treated for neuropathic and nonneuropathic bladder disease. ( 8178380 )
1994
32
Alterations to the electrophysiology of isolated human detrusor smooth muscle cells in bladder disease. ( 8309000 )
1994
33
Cigarette smoking and parity as risk factors for the development of symptomatic gall bladder disease in women: results of the Royal College of General Practitioners' oral contraception study. ( 8307429 )
1994
34
Risk factors for symptomatic gall bladder disease. ( 7959216 )
1994
35
Risk factors for the development of gall bladder disease. ( 18668936 )
1994
36
Is gallbladder ejection fraction a reliable predictor of acalculous gall bladder disease? ( 8321495 )
1993
37
Superficial bladder disease: case studies and therapeutic advances. ( 1466118 )
1992
38
Is gall bladder ejection fraction a reliable predictor of acalculous gall bladder disease? ( 1465273 )
1992
39
Gall bladder disease as seen in a Harare referral hospital centre. ( 2225019 )
1990
40
Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. ( 2925272 )
1989
41
Gall bladder disease: an analytical report of 250 cases. ( 2634700 )
1989
42
Parathyroid hormone like bioactivity measured by cytochemical bioassay in a patient with malignant bladder disease. ( 3248932 )
1988
43
Gall bladder disease in Zimbabwe. ( 3194957 )
1988
44
Looking for gall bladder disease in the patient's iris. ( 3147081 )
1988
45
A critical reappraisal of cystometry in neurogenic bladder diseases. ( 3686758 )
1987
46
A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. ( 2442415 )
1987
47
Urine eosinophil cationic protein in painful bladder disease. ( 3304514 )
1987
48
Prospective study of intravesical dimethyl sulphoxide in the treatment of chronic inflammatory bladder disease. ( 3828709 )
1987
49
Urinary excretion of a metabolite of histamine (1,4-methyl-imidazole-acetic-acid) in painful bladder disease. ( 3567484 )
1987
50
Painful bladder disease: clinical and pathoanatomical differences in 115 patients. ( 3625848 )
1987

Variations for Bladder Disease

Expression for Bladder Disease

Search GEO for disease gene expression data for Bladder Disease.

Pathways for Bladder Disease

Pathways related to Bladder Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.19 CHRM3 MCU P2RX2 P2RX3
2 10.23 CRP IL6

GO Terms for Bladder Disease

Cellular components related to Bladder Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of nuclear inner membrane GO:0005639 8.62 P2RX2 P2RX3

Biological processes related to Bladder Disease according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.65 CRP IDO1 IL6 TAC1 TRPV1
2 excitatory postsynaptic potential GO:0060079 9.58 P2RX2 P2RX3 TRPV1
3 positive regulation of calcium-mediated signaling GO:0050850 9.51 P2RX2 P2RX3
4 positive regulation of calcium ion transport into cytosol GO:0010524 9.49 P2RX2 P2RX3
5 response to carbohydrate GO:0009743 9.48 P2RX2 P2RX3
6 peristalsis GO:0030432 9.46 P2RX2 P2RX3
7 positive regulation of acute inflammatory response GO:0002675 9.43 IL6 TAC1
8 negative regulation of lipid storage GO:0010888 9.37 CRP IL6
9 response to heat GO:0009408 9.33 IL6 P2RX3 TRPV1
10 purinergic nucleotide receptor signaling pathway GO:0035590 9.32 P2RX2 P2RX3
11 behavioral response to pain GO:0048266 9.13 P2RX2 P2RX3 TRPV1
12 urinary bladder smooth muscle contraction GO:0014832 8.8 P2RX2 P2RX3 TRPV1

Molecular functions related to Bladder Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.33 P2RX2 P2RX3 TRPV1
2 extracellular ATP-gated cation channel activity GO:0004931 8.96 P2RX2 P2RX3
3 purinergic nucleotide receptor activity GO:0001614 8.62 P2RX2 P2RX3

Sources for Bladder Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....